168161-89-5

Downstream Products

• 168161-92-0 1-{1-(3,3-Dimethyl-2-oxo-butyl)-2-oxo-5-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl}-3-m-tolyl-urea 
• 168161-91-9 {1-(3,3-Dimethyl-2-oxo-butyl)-2-oxo-5-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl}-carbamic acid benzyl ester 
• 168161-90-8 {2-Oxo-5-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl}-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Process of preparing benzodiazepine compounds useful as antagonists of CCK or of gastrine

A benzodiazepine derivative of formula I, or a pharmaceutically acceptable salt thereof: STR1 wherein: (a) R4 is an alkyl, cycloalkyl or aryl group. (b) R10 is chosen from halo, OH, CH3, OCH3, NR11 R12, NO2, NHCHO, CO2 H and CN, and R11 and R12 are independently selected from H and alkyl (C1 -C5) or together NR11 R12 form a cyclic structure II, STR2 wherein a is 1-6; and (c) R2 is an aromatic 5- or 6-membered, substituted or unsubstituted heterocycle containing at least two heteroatoms of which at least one is nitrogen. These compounds are gastrin and/or CCK-B receptor antagonists.